Pharmacogenetic testing in psychiatry: a review of features and clinical realities.
This article focuses on the first generation of pharmacogenetic tests that are potentially useful in psychiatry. All pharmacogenetic tests currently on the market, or soon to be marketed in psychiatry, for which some information has been published in peer-reviewed journal articles (or abstracts), were selected. Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system. After reviewing these tests, three practical aspects of implementing pharmacogenetic testing in psychiatric clinical practice are briefly reviewed: (1) the evaluation of these tests in clinical practice, (2) cost-effectiveness, and (3) regulatory oversight. Finally, the future of these and other pharmacogenetic tests in psychiatry is discussed.
de Leon
José
J
University of Kentucky Mental Health Research Center at Eastern State Hospital, 627 West Fourth Street, Lexington, KY 40508, USA. jdeleon@uky.edu
Arranz
Maria J
MJ
Ruaño
Gualberto
G
D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D005820:Genetic Testing / Q000191:economics / Q000379:methods; D005838:Genotype; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics / Q000191:economics / Q000379:methods* / Q000639:trends; D011570:Psychiatry / Q000191:economics / Q000379:methods* / Q000639:trends
D003577:Cytochrome P-450 Enzyme System